Fennec Pharmaceuticals Inc. (FRX) Analysts See $-0.19 EPS

March 15, 2018 - By Ellis Scott

 Fennec Pharmaceuticals Inc. (FRX) Analysts See $ 0.19 EPS

Analysts expect Fennec Pharmaceuticals Inc. (TSE:FRX) to report $-0.19 EPS on March, 29.They anticipate $0.08 EPS change or 72.73 % from last quarter’s $-0.11 EPS. After having $-0.19 EPS previously, Fennec Pharmaceuticals Inc.’s analysts see 0.00 % EPS growth. The stock increased 0.33% or $0.04 during the last trading session, reaching $12.11. About 200 shares traded. Fennec Pharmaceuticals Inc. (TSE:FRX) has 0.00% since March 15, 2017 and is . It has underperformed by 16.70% the S&P500.

Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. The company has market cap of $223.51 million. The Company’s lead product candidate is the Sodium Thiosulfate, a water soluble thiol compound that acts as a chemical reducing agent, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. It currently has negative earnings. The firm was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014.

More notable recent Fennec Pharmaceuticals Inc. (TSE:FRX) news were published by: Globenewswire.com which released: “Fennec Pharmaceuticals Announces Listing on the Nasdaq Capital Market” on September 11, 2017, also Streetinsider.com with their article: “Wedbush Starts Fennec Pharmaceuticals (FENC) at Outperform” published on March 12, 2018, Marketwatch.com published: “Fennec Pharmaceuticals Inc.” on October 15, 2017. More interesting news about Fennec Pharmaceuticals Inc. (TSE:FRX) were released by: Seekingalpha.com and their article: “Otonomy’s $525 Million Dive Is Fennec’s Good Fortune” published on November 02, 2017 as well as Seekingalpha.com‘s news article titled: “Fennec Pharma’s lead product candidate shows treatment benefit in late-stage …” with publication date: September 13, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: